Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis

Life Sciences

Volumn 159, Issue , 2016, Pages 43-48

  Sestito, Rosanna ^a   Cianfrocca, Roberta ^a   Rosanò, Laura ^a   Tocci, Piera ^a   Di Castro, Valeriana ^a   Caprara, Valentina ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemoresistance; Endothelin 1; Macitentan; Ovarian carcinoma; Vasculogenic mimicry

Indexed keywords

CISPLATIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MACITENTAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; ZIBOTENTAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL PLASTICITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; SULFONAMIDES;

EID: 84954304722     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.01.009     Document Type: Article

References (30)

1. [1] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 62 (2012), 10–29.
2. [2] Banerjee, S., Kaye, S.B., New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 19 (2013), 961–968.
3. [3] Rosanò, L., Spinella, F., Bagnato, A., Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13 (2013), 637–651.
4. [4] Shenoy, S.K., Lefkowitz, R.J., β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32 (2011), 521–533.
5. [5] Rosanò, L., Cianfrocca, R., Masi, S., Spinella, F., Di Castro, V., Biroccio, A., et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2806–2811.
6. [6] Rosanò, L., Cianfrocca, R., Tocci, P., Spinella, F., Di Castro, V., Spadaro, F., et al. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 32 (2013), 5066–5077.
7. [7] Rosanò, L., Cianfrocca, R., Tocci, P., Spinella, F., Di Castro, V., Caprara, V., et al. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 74 (2014), 7453–7464.
8. [8] Salani, D., Taraboletti, G., Rosanò, L., Di Castro, V., Borsotti, P., Giavazzi, R., et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157 (2000), 1703–1711.
9. [9] Spinella, F., Garrafa, E., Di Castro, V., Rosanò, L., Nicotra, M.R., Caruso, A., et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 69 (2009), 2669–2676.
10. [10] Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14 (2008), 28–36.
11. [11] Kandalaft, L.E., Facciabene, A., Buckanovich, R.J., Coukos, G., Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 15 (2009), 4521–4528.
12. [12] Kim, S.J., Kim, J.S., Kim, S.W., Brantley, E., Yun, S.J., He, J., et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of Paclitaxel by modulating survival pathways in orthototic models of metastatic human ovarian cancer. Neoplasia 13 (2011), 167–179.
13. [13] Kim, S.J., Kim, J.S., Kim, S.W., Yun, S.J., He, J., Brantley, E., et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl. Oncol. 5 (2012), 39–47.
14. [14] Coffman, L., Mooney, C., Lim, J., Bai, S., Silva, I., Gong, Y., et al. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol. Ther. 14 (2013), 184–192.
15. [15] Kim, S.J., Lee, H.J., Kim, S.W., Choi, H.J., He, J., Wu, Q., et al. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin. Cancer Res., 2015, 10.1158/1078–0432 [e-pub ahead of print 23 June 2015].
16. [16] Dome, B., Timar, J., Dobos, J., Meszaros, L., Raso, E., Paku, S., et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66 (2006), 7341–7347.
17. [17] Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155 (1999), 739–752.
18. [18] Sood, A.K., Seftor, E.A., Fletcher, M.S., Gardner, L.M., Buller, R.E., et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158 (2001), 1279–1288.
19. [19] Sood, A.K., Fletcher, M.S., Zahn, C.M., Gruman, L.M., Coffin, J.E., Seftor, E.A., et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol. Ther. 1 (2002), 661–664.
20. [20] Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M.R., Lucidi, A., Ferrandina, G., Natali, P.G., Bagnato, A., Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res. 17 (2011), 2350–2360.
21. [21] Latifi, A., Abubaker, K., Castrechini, N., Ward, A.C., Liongue, C., Dobill, F., et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem. 11 (2011), 22850–22864.
22. [22] Ahmed, N., Abubaker, K., Findlay, J., Quinn, M., Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 10 (2010), 268–278.
23. [23] Polyak, K., Weinberg, R.A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9 (2009), 265–273.
24. [24] Kirschmann, D.A., Seftor, E.A., Hardy, K.M., Seftor, R.E., Hendrix, M.J., Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin. Cancer Res. 18 (2012), 2726–2732.
25. [25] Tang, H.S., Feng, Y.J., Yao, L.Q., Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int. J. Gynecol. Cancer 19 (2009), 605–610.
26. [26] Francescone, R., Scully, S., Bentley, B., Yan, W., Taylor, S.L., Oh, D., et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J. Biol. Chem. 287 (2012), 24821–24831.
27. [27] Yao, X., Ping, Y., Liu, Y.Y., Chen, K., Yoshimura, T., Liu, M., et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by glioma stem-like cells. PloS One, 8, 2013, e57188.
28. [28] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
29. [29] Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., et al. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
30. [30] Del Bufalo, D., Di Castro, V., Biroccio, A., Varmi, M., Salani, D., Rosanò, L., et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel induced apoptosis: requirement for Akt activation. Mol. Pharmacol. 61 (2002), 524–532.